Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT | BioSpace

[anonymous]

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT | BioSpace

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT | BioSpace

 

[anonymous]

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT | BioSpace

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT | BioSpace

Doh!

“These mixed results roused concerns among some executives in Novartis, STAT reported in February 2024, citing two separate anonymous sources. The $2.9 billion deal allows Novartis to drop out of the acquisition in case the FDA rejects MorphoSys’ bid to file an application for pelabresib.”